Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Lana Castellucci et al, adding:
“Important paper for clinical practice.
A large study, independent of the pharma industry, found that in the setting of acute venous thrombosis, the risk of clinically relevant bleeding was:
- 3.3 percent with Apixaban
- 7.3 percent with Rivaroxaban
This difference was significant.
Congratulations to Lana Castellucci for coordinating this multicentre study.
We await the results of their AF study with interest.
Considering how many patients worldwide are on these drugs, this will be an impactful study.
The attached figure gives the summary.
The original article in this week’s New England Journal of Medicine is behind a paywall.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 16:36Muhammad Bilal: Principles and Clinical Uses of the Coombs Test
-
Mar 13, 2026, 16:27Nikhil Ganjoo: Early Detection of Rare Diseases Through Newborn Genome Sequencing
-
Mar 13, 2026, 16:18Tareq Abadl: Anemia of Inflammation – Hepcidin Regulation of Iron
-
Mar 13, 2026, 16:15New Evidence From the COBRRA Trial in Acute VTE – THANZ
-
Mar 13, 2026, 16:09Wolfgang Miesbach: Brussels Will Be the Perfect Stage for EAHAD 2027
-
Mar 13, 2026, 15:59Nicola Pozzi: A Brand-New Mechanism to Reduce Thrombosis Without Increasing Bleeding Risk
-
Mar 13, 2026, 15:47Heghine Khachatryan: Real-World Data on DOAC Use in Pediatric Oncology
-
Mar 13, 2026, 15:29Megan Adediran: Heavy Period as a Sign of a Underlying Bleeding Disorder
-
Mar 13, 2026, 15:28Gareth Owens: Preventing Aortic Dissection Through Post-Mortem Genetics Testing